PEG Ratio

The PEG ratio (price-to-earnings divided by earnings growth rate) of 4.84x means that for each 1% of expected earnings growth, investors are paying $4.84 per share—a high price relative to growth.

This is far above the healthcare sector median of 0.77x, placing Amgen in the 91st percentile among its peers, indicating it is much more expensive than most comparable companies. The year-over-year change is N/A, the quarter-over-quarter change is N/A, and no trend direction is available for the last eight quarters, so there is no historical context to assess whether this valuation is improving or worsening. The combination of a very high PEG ratio with no trend data leaves an ambiguous risk profile—it implies expensive valuation but without confirmation of rising or falling momentum. This metric supports the overall NEUTRAL verdict by suggesting the stock’s price may be stretched, reinforcing the need for caution and a wait-and-see approach.

Frequently Asked Questions

Closest Sector Peers